BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gu W, Tong Z. Sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) and microvascular infiltration: a systematic review and meta-analysis. J Int Med Res 2020;48:300060520946872. [PMID: 32815430 DOI: 10.1177/0300060520946872] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Zheng Z, Guan R, Jianxi W, Zhao Z, Peng T, Liu C, Lin Y, Jian Z, Wu YS. Microvascular Invasion in Hepatocellular Carcinoma: A Review of Its Definition, Clinical Significance, and Comprehensive Management. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/9567041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
2 Liu W, Quan B, Lu S, Tang B, Li M, Chen R, Ren Z, Yin X. First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. Front Oncol 2021;11:771045. [PMID: 35004289 DOI: 10.3389/fonc.2021.771045] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Wang JH, Chen YY, Kee KM, Wang CC, Tsai MC, Kuo YH, Hung CH, Li WF, Lai HL, Chen YH. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab. Cancers (Basel) 2022;14:343. [PMID: 35053508 DOI: 10.3390/cancers14020343] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]